Guochun Gong

This inventor holds 19 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Gene Editing Technology. Top assignees: Regeneron Pharmaceuticals, Inc., Harvard College, Regeneran Pharmaceuticals, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guochun Gong. Retrieved from https://idiyas.com/inventor/guochun-gong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 17)

% Patents Active = 94.7

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 5 (Patent Applications = 17)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 44(Granted Patents)

Location History:

Elmsford, NY (US) (2013 - 2019)
Pleasantville, NY (US) (2020 - 2024)

Company Filing History:

18 out of 1,488

Regeneron Pharmaceuticals, Inc.

Regeneran Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

CRISPR

Gene Expression

Transcription Modulation

Stem Cells

Disease Modeling

Embryonic Stem Cells

Neonatal Progeroid Syndrome

Type 2 Diabetes

C9ORF72 Locus

LincRNA

AAV Strategies

Fibrillin-1 Mutations

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12582104 - MUTANT MYOCILIN DISEASE MODEL AND USES THEREOF (2026-03-24),

2. 12529072 - TRANSCRIPTION MODULATION IN ANIMALS USING CRISPR/CAS SYSTEMS (2026-01-20),

3. 12521451 - CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy (2026-01-13),

4. 11866794 - Cas-ready mouse embryonic stem cells and mice and uses thereof (2024-01-09),

5. 11730150 - Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy (2023-08-22),

6. 11547101 - Non-human animals having a disruption in a C9ORF72 locus (2023-01-10),

7. 11547100 - Method for screening gene expression in lincRNA-deficient mice or rats (2023-01-10),

8. 11519004 - Transcription modulation in animals using CRISPR/Cas systems (2022-12-06),

9. 11130999 - Cas-ready mouse embryonic stem cells and mice and uses thereof (2021-09-28),

10. 11021719 - Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo (2021-06-01),

11. 10548302 - Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy (2020-02-04),

12. 10285388 - Non-human animals having a disruption in a C9ORF72 locus (2019-05-14),

13. 10196613 - Stem cells for modeling type 2 diabetes (2019-02-05),

14. 9677086 - Promoter-regulated differentiation-dependent self-deleting cassette (2017-06-13),

15. 9554564 - IncRNA-knockout mice (2017-01-31),

Title: Guochun Gong - Pioneering Inventor from Elmsford, NY

Introduction: Guochun Gong is a renowned inventor hailing from Elmsford, NY, known for his groundbreaking contributions to various technological fields.

Latest Patents: Guochun Gong holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovation.

Career Highlights: With over two decades of experience in the industry, Guochun Gong has worked with leading tech companies and research institutions, consistently pushing the boundaries of innovation.

Collaborations: Throughout his career, Guochun Gong has collaborated with top scientists, engineers, and researchers, fostering a culture of creativity and excellence in all his projects.

Conclusion: Guochun Gong's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.